Immunic Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Immunic heeft een totaal eigen vermogen van $151.2M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $189.7M en $38.5M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$186.63m
Aandelen	US$151.23m
Totaal verplichtingen	US$38.51m
Totaal activa	US$189.74m

Recente financiële gezondheidsupdates

Analyse-artikel • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analyse-artikel • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyse-artikel • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Recent updates

Analyse-artikel • Oct 17

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse-artikel • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyse-artikel • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.

Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.

Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2 $88.1 million.

Analyse-artikel • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $188.8M ) IMUX } overtreffen de korte termijn passiva ( $38.4M ).

Langlopende schulden: De kortetermijnactiva IMUX ( $188.8M ) overtreffen de langetermijnschulden ( $146.0K ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IMUX is schuldenvrij.

Schuld verminderen: IMUX heeft de afgelopen 5 jaar geen schulden gehad.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: IMUX heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: IMUX heeft voldoende kasruimte voor 1.3 jaar als de vrije kasstroom blijft dalen met een historisch percentage van 10.3 % per jaar.

Ontdek gezonde bedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/07/13 14:48
Aandelenkoers aan het einde van de dag	2026/07/10 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Immunic, Inc. wordt gevolgd door 18 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
George Farmer	BMO Capital Markets Equity Research
William Wood	B. Riley Securities, Inc.
Tyler Bussian	Brookline Capital Markets

Immunic Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Recent updates

Immunic, Inc. Announces Board and Committee Changes

Immunic, Inc., Annual General Meeting, Jun 29, 2026

Immunic, Inc. Announces Chief Executive Officer Changes

Price target decreased by 10% to US$44.67

Immunic, Inc. Appoints Michael W. Bonney as Chair of the Board of Directors, Effective May 16, 2026

Immunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026

Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026

Price target increased by 11% to US$5.00

No longer forecast to breakeven

New major risk - Negative shareholders equity

Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investors

Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple Sclerosis

Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investors

Immunic, Inc. Plans Transition of Daniel Vitt from CEO

New minor risk - Share price stability

Immunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price Rule

Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026

Forecast to breakeven in 2028

New major risk - Shareholder dilution

New minor risk - Profitability

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

Price target decreased by 11% to US$6.83

Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

New major risk - Financial position

No longer forecast to breakeven

Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price Requirement

Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Independent Director recently bought US$100k worth of stock

Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MS

Price target decreased by 8.3% to US$12.55

Immunic, Inc. has announced a Derivatives Offering.

New major risk - Negative shareholders equity

New minor risk - Share price stability

Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple Sclerosis

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Immunic, Inc., Annual General Meeting, Jun 04, 2025

Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $5.1 million.

Immunic, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Price target increased by 7.0% to US$13.12

Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

New minor risk - Market cap size

Independent Director recently bought US$100k worth of stock

No longer forecast to breakeven

Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID Syndrome

Price target decreased by 13% to US$11.90

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

New major risk - Financial position

Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Immunic, Inc. Appoints Simona Skerjanec as Member of the Board

Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and President

New minor risk - Profitability

No longer forecast to breakeven

Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Immunic, Inc., Annual General Meeting, Jun 11, 2024

Price target decreased by 32% to US$9.00

Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024

New major risk - Shareholder dilution

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.